Submitted abstractsHead and neck cancer1016TiP - A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
Head and neck cancer
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2016 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.